We evaluated the prognosis of 357 metastatic RCC patients who received VEGFR-TKI or cytokine as initial systemic therapy in the era of molecular-targeted therapy (MTT) and the clinical usefulness of the JMRC prognostic classification. The present study showed for the first time the prognosis of Japanese patients with metastatic RCC in the era of MTT.
The JMRC prognostic classification had been developed as a clinically available prognostic classification for overall survival in metastatic RCC patients in the cytokine era (Shinohara N, et al. Cancer Sci 2012). From the present study, this classification is also clinically useful as a prognostic model (PFS and OS) in metastatic RCC patients in the era of MTT. We therefore believe that the JMRC prognostic classification would be very important in Asian patients with metastatic RCC.
Written by:
Nobuo Shinohara, MD
Department of Renal and Genitourinary Surgery
Hokkaido University Graduate School of Medicine